Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 3, 2016, Pages 306-314

  Salvo, F ^a,b   Pariente, A ^a,b,c   Shakir, S ^d   Robinson, P ^c,e   Arnaud, M ^a   Thomas, S H L ^f   Raschi, E ^g   Fourrier Reglat, A ^a,b   Moore, N ^a,b,c   Sturkenboom, M ^h   Hazell, L ^d  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c Centre of Clinical Investigation Clinical Epidemiology   (France)

^d DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^e ADERA   (France)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ERG1 POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG;

ARTICLE; CASE CONTROL STUDY; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; ODDS RATIO; PRIORITY JOURNAL; RISK; SIDE EFFECT; SUDDEN CARDIAC DEATH; SUDDEN DEATH; ANTAGONISTS AND INHIBITORS; DEATH, SUDDEN, CARDIAC; IC50;

ANTIPSYCHOTIC AGENTS; DEATH, SUDDEN, CARDIAC; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INHIBITORY CONCENTRATION 50; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84958969139     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.250     Document Type: Article

References (48)

1. Ray W.A., Chung C.P., Murray K.T., Hall K., & Stein C.M. Atypical antipsychotic drugs, and the risk of sudden cardiac death. N. Engl. J. Med. 360, 225-235 (2009
2. Jolly K., Gammage M.D., Cheng K.K., Bradburn P., Banting M.V., & Langman M.J.S. Sudden death in patients receiving drugs tending to prolong the QT interval. Br. J. Clin. Pharmacol. 68, 743-751 (2009
3. Trudeau M.C., Warmke J.W., Ganetzky B., & Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269, 92-95 (1995
4. Reilly J.G., Ayis S.A., Ferrier I.N., Jones S.J., & Thomas S.H. QTcinterval abnormalities, and psychotropic drug therapy in psychiatric patients. Lancet 355, 1048-1052 (2000
5. Mehta S., Chen H., Johnson M., & Aparasu R.R. Risk of serious cardiac events in older adults using antipsychotic agents. Am. J. Geriatr. Pharmacother. 9, 120-132 (2011
6. Jones M.E., et al. Risk of mortality (including sudden cardiac death), and major cardiovascular events in users of olanzapine, and other antipsychotics: a study with the general practice research database. Cardiovasc. Psychiatry. Neurol. 2013, 647476 (2013
7. Kenbubpha K., & Silpakit C. Association between antipsychotics, and sudden death in psychotic in-patients. Int. Med. J. 9, 27-31 (2002
8. Reilly J.G., Ayis S.A., Ferrier I.N., Jones S.J., & Thomas S.H. Thioridazine, and sudden unexplained death in psychiatric in-patients. Br. J. Psychiatry 180, 515-522 (2002
9. Van Noord C., Sturkenboom M.C.J.M., Straus S.M.J.M., Witteman J.C.M., & Stricker B.H.C. Non-cardiovascular drugs that inhibit hERGencoded potassium channels, and risk of sudden cardiac death. Heart 97, 215-220 (2011
10. Wells G.A., et al. The Newcastle-Ottawa Scale (NOS). for assessing the quality of nonrandomised studies in meta-analyses 2010 10 January 2014. www.ohri.ca/Programs/clinical-epidemiology/oxford.asp
11. DerSimonian R., & Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177-188 (1986
12. Jackson D., White I.R., & Thompson S.G. Extending DerSimonian, and Laird?s methodology to perform multivariate random effects meta-analyses. Stat. Med. 29, 1282-1297 (2010
13. Van Houwelingen H.C., Arends L.R., & Stijnen T. Advanced methods in meta-analysis: multivariate approach, and meta-regression. Stat. Med. 21, 589-624 (2002
14. Raudenbush S.W. Random effects models. In The Handbook of Research Synthesis (eds. Foundation RS). pp. 301-321 (New York H. Cooper, & L. V. Hedges, 1994
15. Lopez-Lopez J.A., Marin-Martinez F., Sanchez-Meca J., Van Den Noortgate W., & Viechtbauer W. Estimation of the predictive power of the model in mixed-effects meta-regression: a simulation study. Br. J. Math. Stat. Psychol. (2013
16. Crumb W.J.J., et al. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm. Res. 23, 1133-1143 (2006
17. Lee S.Y., Kim Y.J., Kim K.T., Choe H., & Jo S.H. Blockade of HERG human K1 channels, and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br. J. Pharmacol. 148, 499-509 (2006
18. Tie H., et al. Clozapine, and sudden death. J. Clin. Psychopharmacol. 21, 630-632 (2001
19. Hennessy S., et al. Cardiac arrest, and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 325, 1070 (2002
20. Fitzsimons J., Berk M., Lambert T., Bourin M., & Dodd S. A review of clozapine safety. Expert. Opin. Drug. Saf. 4, 731-744 (2005
21. Titier K., et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia, and sudden death in clinical practice. Toxicol. Appl. Pharmacol. 199, 52-60 (2004
22. Leonard C.E., et al. Antipsychotics, and the risks of sudden cardiac death, and all-cause death: cohort studies in Medicaid, and duallyeligible Medicaid-Medicare beneficiaries of five states. J. Clin. Exp. Cardiolog. Suppl 10, 1-9 (2013
23. Modai I., et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J. Clin. Psychopharmacol. 20, 325-327 (2000
24. Adabag S., et al. Obesity related risk of sudden cardiac death in the atherosclerosis risk in communities study. Heart 101, 215-221 (2015
25. Sutton A.J. Methods for Meta-Analysis in Medical Research (Wiley, New York, 2000
26. McGettigan P., & Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS. Med. 8, e1001098 (2011
27. Varas-Lorenzo C., et al. Myocardial infarction, and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol. Drug. Saf. 22, 559-570 (2013
28. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol. Rev. 9, 1-30 (1987
29. Morgenstern H. Uses of ecologic analysis in epidemiologic research. Am. J. Public. Health 72, 1336-1344 (1982
30. Higgins J.P.T. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. http://www.cochranehandbook.org (2011
31. Liberati A., et al. The PRISMA statement for reporting systematic reviews, and meta-analyses of studies that evaluate health care interventions: explanation, and elaboration. PLoS. Med. 6, e1000100 (2009
32. Stroup D.F., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE). group. JAMA 283, 2008-2012 (2000
33. Higgins J.P., & Thompson S.G. Quantifying heterogeneity in a metaanalysis. Stat. Med. 21, 1539-1558 (2002
34. Drolet B., Yang T., Daleau P., Roden D.M., & Turgeon J. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J. Cardiovasc. Pharmacol. 41, 934-937 (2003
35. Fossa A.A., et al. Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. Eur. J. Pharmacol. 486, 209-221 (2004
36. Guo L., & Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J. Pharmacol. Toxicol. Methods 52, 123-135 (2005
37. Hanson L.A., Bass A.S., Gintant G., Mittelstadt S., Rampe D., & Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J. Pharmacol. Toxicol. Methods 54, 116-129 (2006
38. Katchman A.N., Koerner J., Tosaka T., Woosley R.L., & Ebert S.N. Comparative evaluation of HERG currents, and QT intervals following challenge with suspected torsadogenic, and nontorsadogenic drugs. J. Pharmacol. Exp. Ther. 316, 1098-1106 (2006
39. Kim K.S., & Kim E.J. The phenothiazine drugs inhibit hERG potassium channels. Drug. Chem. Toxicol. 28, 303-313 (2005
40. Kirsch G.E., et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature, and stimulus pattern. J. Pharmacol. Toxicol. Methods 50, 93-101 (2004
41. Kongsamut S., Kang J., Chen X.L., Roehr J., & Rampe D. A comparison of the receptor binding, and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 450, 37-41 (2002
42. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., & Gintant G.A. The utility of hERG, and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J. Cardiovasc. Pharmacol. 43, 369-379 (2004
43. Milnes J.T., Witchel H.J., Leaney J.L., Leishman D.J., & Hancox J.C. hERG K1 channel blockade by the antipsychotic drug thioridazine: an obligatory role for the S6 helix residue F656. Biochem. Biophys. Res. Commun. 351, 273-280 (2006
44. Morissette P., Hreiche R., Mallet L., Vo D., Knaus E.E., & Turgeon J. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J. Psychopharmacol. 21, 735-741 (2007
45. Silvestre J.S., & Prous J.R. Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods. Find. Exp. Clin. Pharmacol. 29, 457-465 (2007
46. Yao X., et al. Predicting QT prolongation in humans during early drug development using hERG inhibition, and an anaesthetized guinea-pig model. Br. J. Pharmacol. 154, 1446-1456 (2008
47. Sturkenboom M. ARITMO: arrhythmogenic potential of drugs. Project Final Report. http://cordis.europa.eu/docs/results/241679/final1-aritmo-final-report-v2-0final.pdf (2013
48. Viechtbauer W. Conducting meta-analyses in R with the metafor. J. Stat. Soft. 36, 1-48 (2010